Bolsas y Mercados Españoles
Company
search
ORYZON GENOMICS, S.A.
AddressCL/ SANT FERRAN 74, 08940 CORNELLA DE LLOBREGAT 
Listed Capital1,708,069.55 Euros

 


ORYZON GENOMICS
ISINES0167733015 TickerORY Nominal0.05 MarketContinuous Market Admitted Capital1,708,069.55 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
13/12/201709:57- 2.8600-1.402.82002.86002.82002.834826,83276,064.43
12/12/2017Close2.86002.9600-3.382.86002.99002.85002.9049136,341396,057.48

Last pay
TypeEx-datePayment DateConcept
 

Last split
DateEquivalence
 

Last reverse split
DateEquivalence
 

Last capital increase
PeriodProportionType
05/04/2017 - 05/04/201720 x 100Premium


 2017
until 12/12
20162015  
Capitalisation *
(thousands of euros)
97,702123,807102,484  
Shares
(x 1,000)
34,16128,46828,468  
Period Close Price
(euros)
2.86004.34903.6000  
Period Last Price
(euros)
2.86004.34903.6000  
Period High Price
(euros)
4.83305.20005.2500  
Period Low Price
(euros)
1.75002.55003.4500  
Volume
(thousands of shares)
33,4629,9481,547  
Turnover
(thousands of euros)
95,13941,2206,768  

Profile

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon’s LSD1 program is currently covered by 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets.

The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization.

The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.

Source: Issuing company.
13/12/2017 00:00:56

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Follow us in:
Copyright © Bolsas y Mercados Españoles 2017

MARKET STATUS

The Market Status informs through quick and easy-to-read notices on incidents affecting the Equity markets as well as Indices and financial systems operated by BME.

If an issue occurs, the message "TRADING" will change to "MARKET ISSUE" to reflect that a market event has occurred. By clicking on the Issue of the published alert it will be possible to access the information and intraday updates associated with this incident, which will be published immediately.

Note: BME will use its discretion to assign the severity of an incident